Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Jayamas Medica Industri TbkISX:OMED -0.88%90 ROC (Joel Greenblatt) % is 44.17% as of Jun. 2026, which is 17% below its 10-year median of 53.44. GuruFocus rates ISX:OMED with a GF Score™ of 90/100 and a GF Value™ of Rp238.63 (Fairly Valued). The stock has 2 warning signs investors should review. Among 837 Medical Devices & Instruments companies, PT Jayamas Medica Industri Tbk ranks better than 85.54% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. PT Jayamas Medica Industri Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 44.17%.
The historical rank and industry rank for PT Jayamas Medica Industri Tbk's ROC (Joel Greenblatt) % or its related term are showing as below:
ISX:OMED'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 34.51 Med: 53.44 Max: 239.14
Current: 41.24
During the past 7 years, PT Jayamas Medica Industri Tbk's highest ROC (Joel Greenblatt) % was 239.14%. The lowest was 34.51%. And the median was 53.44%.
ISX:OMED's ROC (Joel Greenblatt) % is ranked better than 85.54% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 4.48
vs ISX:OMED: 41.24
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk ROC (Joel Greenblatt) % Chart
ISX:OMED vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, PT Jayamas Medica Industri Tbk's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Jayamas Medica Industri Tbk ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Jayamas Medica Industri Tbk's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where PT Jayamas Medica Industri Tbk's ROC (Joel Greenblatt) % falls into.
PT Jayamas Medica Industri Tbk ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 44.17% mean?
PT Jayamas Medica Industri Tbk (ISX:OMED) has a ROC (Joel Greenblatt) % of 44.17% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on PT Jayamas Medica Industri Tbk and its competitors. This is 17% below median its historical median of 53.44. Over the past decade, PT Jayamas Medica Industri Tbk's ROC (Joel Greenblatt) % has ranged from 34.51 to 239.14. According to the industry distribution chart, PT Jayamas Medica Industri Tbk ranks #121 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 14.5%.
Is PT Jayamas Medica Industri Tbk's ROC (Joel Greenblatt) % too high?
PT Jayamas Medica Industri Tbk's current ROC (Joel Greenblatt) % of 44.17% is 17% below median its 10-year median of 53.44. Over the past 10 years, this metric has ranged from a low of 34.51 to a high of 239.14. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.48. PT Jayamas Medica Industri Tbk's value of 44.17% is 885.9% above this industry median. Based on the distribution chart, PT Jayamas Medica Industri Tbk ranks #121 out of 837 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PT Jayamas Medica Industri Tbk ranks #121 out of 837 companies for ROC (Joel Greenblatt) %. This places PT Jayamas Medica Industri Tbk in the top 15% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.48. PT Jayamas Medica Industri Tbk's value of 44.17% is 885.9% above this benchmark. Historically, PT Jayamas Medica Industri Tbk's own ROC (Joel Greenblatt) % has ranged from 34.51 to 239.14 over the past decade. While the company's 10-year median is 53.44 vs. the industry median of 4.48, PT Jayamas Medica Industri Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.48, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Jayamas Medica Industri Tbk's current ROC (Joel Greenblatt) % of 44.17% is 885.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on PT Jayamas Medica Industri Tbk and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Jayamas Medica Industri Tbk's current ROC (Joel Greenblatt) % is 44.17%, which is 17% below median its own 10-year median of 53.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Fairly Valued. The stock's GF Value™ is Rp238.63, compared to a current price of Rp226.00 — trading 5.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 44.17%, which is 17% below median its 10-year median of 53.44 and 885.9% above the Medical Devices & Instruments industry median of 4.48. PT Jayamas Medica Industri Tbk's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current ROC (Joel Greenblatt) % is 44.17% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued.
The current stock price of Rp226.00 is trading 5.3% below its estimated GF Value™ of Rp238.63.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Fairly Valued.
Key valuation signals for ISX:OMED:
ROC (Joel Greenblatt) %: 44.17% (17% below median its 10-year median of 53.44)
GF Value™: Rp238.63 vs. price of Rp226.00 (5.3% below fair value)
Industry Position: 885.9% above the Medical Devices & Instruments median (#121 of 837)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
90GF Score
Get the complete analysis for ISX:OMED
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
